CAMBRIDGE, United Kingdom and NEW YORK, October 13, 2025 – Artios Pharma Limited (“Artios”), a biopharmaceutical company committed to realizing the therapeutic power of targeting the DNA damage ...
Potential first-in-class, and industry-leading DNA polymerase Theta (Polθ) inhibitor, ART6043 demonstrated an attractive tolerability profile, expected PK/PD activity, and promising clinical signals ...
The MarketWatch News Department was not involved in the creation of this content. -- Potential first-in-class, and industry-leading DNA polymerase Theta (Pol ) inhibitor, ART6043 demonstrated an ...
CAMBRIDGE, United Kingdom and NEW YORK, October 13, 2025 - Artios Pharma Limited ("Artios”), a biopharmaceutical company committed to realizing the therapeutic power of targeting the DNA damage ...
U.S. Fast Track designation of ART6043 underpinned by promising clinical data to date and high unmet need in gBRCA-mutated HER2-negative breast cancer Artios is launching a global randomized Phase 2 ...
Potential first-in-class, and industry-leading DNA polymerase Theta (Polθ) inhibitor, ART6043 demonstrated an attractive tolerability profile, expected PK/PD activity, and promising clinical signals ...
The MarketWatch News Department was not involved in the creation of this content. CAMBRIDGE, United Kingdom and NEW YORK, October 13, 2025 -- Artios Pharma Limited ("Artios"), a biopharmaceutical ...
Mucin 16–Directed Therapy in Pediatric Sarcomas: Case Evidence of Ubamatamab Efficacy in Epithelioid Sarcoma and Its Implications for Other Sarcoma Subtypes We conducted a phase I trial of the ...
SDKI Analytics（本社：東京都渋谷区）は、このたび、2025年01月25に「デオキシリボ核酸（DNA）ポリメラーゼ市場調査レポート：2025－2037年の市場規模、シェア、傾向の予測」を発表しました。デオキシリボ核酸（DNA）ポリメラーゼに関する市場調査レポートには ...
一部の結果でアクセス不可の可能性があるため、非表示になっています。
アクセス不可の結果を表示する